Drug Profile
F-C.OXT-A
Alternative Names: 3'-Fluorocarbocyclic oxetanocin ALatest Information Update: 12 Jan 2004
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Nonindustrial source
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 12 Jan 2004 No development reported - Preclinical for Viral infections in Japan (unspecified route)
- 22 Jun 2001 Preclinical development for Viral infections in Japan (Unknown route)
- 14 Jul 1998 No-Development-Reported for Viral infections in Japan (Unknown route)